Skip to main content

Monoclonal antibodies inhibiting MMP-9 activity alleviate peripheral neuropathy in diabetic mice.

Journal articles  - Journal Article
Lee, KB; He, W; Matsuoka, Y; Bang, S; Krishnan, S; Xu, J; Zhang, Q; Ma, L; Hu, W; Ao, X; Parisien, M; Diatchenko, L; Liu, X; Ji, R-R; Ge, X
Published in: Sci Transl Med
September 9, 2026

Diabetic peripheral neuropathy (DPN) is a debilitating medical condition that affects millions of individuals, causing neuropathic pain and chronic wounds. Despite its substantial impact, there are currently no effective disease-modifying treatments available to prevent or reverse the progression of nerve damage. By regulating neuroinflammation, matrix metalloproteinase-9 (MMP-9) is both sufficient and required for the pathogenesis of neuropathy, representing a promising drug target for DPN; however, small-molecule inhibitors often lack target specificity. We developed a panel of selective, potent, and proteolytically stable monoclonal antibodies (mAbs) that inhibit MMP-9 activity as a treatment for DPN. We found that systematic administration of MMP-9 inhibitory mAbs alleviated mechanical and cold pain symptoms in diabetic mouse models and restored hind paw wound healing in diabetic mice. MMP-9 mAbs also reduced epidermal nerve fiber degeneration in diabetic mice by enhancing nerve mitochondrial function and promoting skin angiogenesis. Furthermore, we determined that MMP-9 expression in human dorsal root ganglia is increased among patients with diabetes, and human genetic analysis revealed that both rare coding of MMP9 and its common variants are associated with neuropathic pain phenotypes. Together, these translational findings indicate that MMP-9-specific mAbs hold potential as disease-modifying therapies for peripheral neuropathy and for reducing lower extremity complications associated with diabetes.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Sci Transl Med

DOI

EISSN

1946-6242

Publication Date

September 9, 2026

Volume

18

Issue

866

Start / End Page

eadw3558

Location

United States

Related Subject Headings

  • Wound Healing
  • Skin
  • Neuralgia
  • Mice, Inbred C57BL
  • Mice
  • Matrix Metalloproteinase Inhibitors
  • Matrix Metalloproteinase 9
  • Male
  • Humans
  • Ganglia, Spinal
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lee, K. B., He, W., Matsuoka, Y., Bang, S., Krishnan, S., Xu, J., … Ge, X. (2026). Monoclonal antibodies inhibiting MMP-9 activity alleviate peripheral neuropathy in diabetic mice. Sci Transl Med, 18(866), eadw3558. https://doi.org/10.1126/scitranslmed.adw3558
Lee, Ki Baek, Wei He, Yutaka Matsuoka, Sangsu Bang, Sushma Krishnan, Jing Xu, Qin Zhang, et al. “Monoclonal antibodies inhibiting MMP-9 activity alleviate peripheral neuropathy in diabetic mice.” Sci Transl Med 18, no. 866 (September 9, 2026): eadw3558. https://doi.org/10.1126/scitranslmed.adw3558.
Lee KB, He W, Matsuoka Y, Bang S, Krishnan S, Xu J, et al. Monoclonal antibodies inhibiting MMP-9 activity alleviate peripheral neuropathy in diabetic mice. Sci Transl Med. 2026 Sep 9;18(866):eadw3558.
Lee, Ki Baek, et al. “Monoclonal antibodies inhibiting MMP-9 activity alleviate peripheral neuropathy in diabetic mice.” Sci Transl Med, vol. 18, no. 866, Sept. 2026, p. eadw3558. Pubmed, doi:10.1126/scitranslmed.adw3558.
Lee KB, He W, Matsuoka Y, Bang S, Krishnan S, Xu J, Zhang Q, Ma L, Hu W, Ao X, Parisien M, Diatchenko L, Liu X, Ji R-R, Ge X. Monoclonal antibodies inhibiting MMP-9 activity alleviate peripheral neuropathy in diabetic mice. Sci Transl Med. 2026 Sep 9;18(866):eadw3558.

Published In

Sci Transl Med

DOI

EISSN

1946-6242

Publication Date

September 9, 2026

Volume

18

Issue

866

Start / End Page

eadw3558

Location

United States

Related Subject Headings

  • Wound Healing
  • Skin
  • Neuralgia
  • Mice, Inbred C57BL
  • Mice
  • Matrix Metalloproteinase Inhibitors
  • Matrix Metalloproteinase 9
  • Male
  • Humans
  • Ganglia, Spinal